Key facts
- It has raised $50K; the latest was Seed Round in May 2025.
- Notable investors include Fit 4 Start, Expon Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Invitrolize
- ·The full record, as it builds
Funding rounds
No funding rounds for Invitrolize are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Invitrolize
Developer of 3D alveolar in vitro models designed to advance early respiratory hazard detection for safer product development. The company specializes in the identification and differentiation of respiratory sensitizers and respiratory irritants under realistic air-liquid interphase exposure conditions, enabling chemical and pharmaceutical organizations to identify problems early for safer, more effective formulations.
- Sector
- Healthcare
- HQ
- Belvaux, Luxembourg
- Founded
- 2021
- Employees
- 5
- Website
- invitrolize.com/
- Ownership
- Privately Held (backing)
Invitrolize doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Invitrolize shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Invitrolize in its N-PORT filings yet. We sweep new filings monthly.